Project 3: The Role of BCL-6 in Germinal Center Formation. The overall goal of this project is to elucidate the biological function of the BCL-6 proto-oncogene and its role in the pathogenesis of non-Hodgkin lymphoma (NHL). BCL-6 is a POZ-zinc finger transcriptional represser required for germinal center (GC) formation, whose expression id frequently deregulated by chromosomal translocation and somatic hypermutation in diffuse large B cell lymphoma (DLBCL). The following specific aims will be pursued: 1. A genome -wide identification of BCL6 target genes in GC B cells by integrating gene expression profiling with biochemical and reverse engineering methods;2. Construction of mouse models of DLBCL by combining BCL6 deregulation with other lesions associated human DLBCL, including IRF4/MUM1 and c-MYC deregulation, and Blimpl inactivation;3. Development and pre-clinical testing of anti-BCL6 therapeutic strategies. """"""""Stabilized Alpha-Helices of Transcription"""""""" (SAHT) molecules directed against BCL6 will be developed in collaboration with Project 5. Anti-BCL6 SAHTs will be tested for their efficacy and specificity against GC-derived lymphomas in DLBCL cell lines and DLBCL mouse models. The proposed studies are relevant for public health since non-Hodgkin lymphomas represent the 5th most common human malignancy and are displaying an increased incidence during the last decade. This project plans to improve the understanding of the pathogenesis of this disease and develop new therapeutic strategies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA092625-10
Application #
8113949
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-06-30
Budget Start
2010-07-21
Budget End
2013-06-30
Support Year
10
Fiscal Year
2010
Total Cost
$478,231
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chapuy, Bjoern; Cheng, Hongwei; Watahiki, Akira et al. (2016) Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127:2203-13
Zhang, Baochun; Calado, Dinis Pedro; Wang, Zhe et al. (2015) An oncogenic role for alternative NF-?B signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep 11:715-26
Carey, Christopher D; Gusenleitner, Daniel; Chapuy, Bjoern et al. (2015) Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn 17:19-30
Gostissa, Monica; Bianco, Julia M; Malkin, Daniel J et al. (2013) Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proc Natl Acad Sci U S A 110:2934-9
Yan, Qingsheng; Xu, Rong; Zhu, Liya et al. (2013) BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol 33:845-57
Ying, Carol Y; Dominguez-Sola, David; Fabi, Melissa et al. (2013) MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol 14:1084-92
Chen, Linfeng; Monti, Stefano; Juszczynski, Przemyslaw et al. (2013) SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23:826-38
Rossi, Davide; Rasi, Silvia; Spina, Valeria et al. (2013) Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121:1403-12
Caro, Pilar; Kishan, Amar U; Norberg, Erik et al. (2012) Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22:547-60
Sander, Sandrine; Calado, Dinis P; Srinivasan, Lakshmi et al. (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22:167-79

Showing the most recent 10 out of 124 publications